Metabolic inflammation in metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 1.3 billion people worldwide and is frequently associated with cardiovascular disease, type 2 diabetes, chronic kidney disease, and other metabolic disorders. A key feature linking these conditions is metabolic inflammation, or metainflammation, a state of chronic, low-grade inflammation driven by excessive lipid accumulation and adipose tissue dysfunction. Metainflammation promotes hepatic steatosis, inflammation, hepatocyte injury and ballooning, and fibrosis, thereby contributing to the development and progression of MASLD, as well as metabolic dysfunction and alcohol-associated liver disease (MetALD), which can lead to liver cirrhosis and hepatocellular carcinoma. These pathological processes are mediated through multiple interconnected mechanisms, including insulin resistance, dysregulated lipid metabolism, oxidative stress, fibrogenesis, and alterations in the gut microbiota. This review discusses the mechanisms underlying metainflammation in MASLD and MetALD and summarizes current and emerging therapeutic strategies targeting these pathogenic factors in preclinical studies and clinical trials.

Authors

Institutions

Publication Details

Journal
World Journal of Immunology
Published
2026-11-20
DOI
https://doi.org/10.5411/wji.125225
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Metabolic inflammation in metabolic dysfunction-associated steatotic liver disease

Ming Yang, Chun-Ye Zhang
4 links
World Journal of Immunology
Liver Disease Diagnosis and Treatment
article

Metabolic inflammation in metabolic dysfunction-associated steatotic liver disease

Ming Yang, Chun-Ye Zhang
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 1.3 billion people worldwide and is frequently associated with cardiovascular disease, type 2 diabetes, chronic kidney disease, and other metabolic disorders. A key feature linking these conditions is metabolic inflammation, or metainflammation, a state of chronic, low-grade inflammation driven by excessive lipid accumulation and adipose tissue dysfunction. Metainflammation promotes hepatic steatosis, inflammation, hepatocyte injury and ballooning, and fibrosis, thereby contributing to the development and progression of MASLD, as well as metabolic dysfunction and alcohol-associated liver disease (MetALD), which can lead to liver cirrhosis and hepatocellular carcinoma. These pathological processes are mediated through multiple interconnected mechanisms, including insulin resistance, dysregulated lipid metabolism, oxidative stress, fibrogenesis, and alterations in the gut microbiota. This review discusses the mechanisms underlying metainflammation in MASLD and MetALD and summarizes current and emerging therapeutic strategies targeting these pathogenic factors in preclinical studies and clinical trials.

World Journal of ImmunologyVol. 16(3)
University of Missouri (US)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon